Trial Profile

An efficacy and safety of Nilotinib vs Imatinib in Albanian Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary) ; Nilotinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

21 Jun 2020 Results evaluating role of Molecular Monitoring Chronic Myeloid Leukemia Patients in Low Income-Countries Like Albania, presented at the 25th Congress of the European Haematology Association
23 Jul 2018 New trial record
17 Jun 2018 Primary endpoint has been met. (Major molecular response (MMR; BCR-ABL1 0.1% on the International Scale) at 12 months)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com